Oncologists Not Discussing Supplement Use With Patients

This article originally appeared here.
Share this content:
Oncologists Not Discussing Supplement Use With Patients
Oncologists Not Discussing Supplement Use With Patients

(HealthDay News) -- Fewer than half of oncologists bring up the subject of herbs or supplements with their patients, with many doctors citing their own lack of information as a major reason why they skip the conversation, according to research published in the Dec. 20 issue of the Journal of Clinical Oncology.

The researchers asked 392 oncologists about their views and knowledge of supplements. The average age of those who responded was 48 years. About three-quarters of them were men, and about three-quarters were white. The specialists polled talked about supplements with 41 percent of their patients. However, doctors initiated only 26 percent of these discussions. The survey also revealed that two out of three oncologists believed they didn't have enough information about herbs and supplements to answer their patients' questions. Of all the doctors surveyed, 59 percent said they had no education on these products.

When asked about a hypothetical patient with a curable form of cancer, 80 percent of the oncologists surveyed said they would actively discourage the use of an unknown herb with chemotherapy. Still, 86 percent of the doctors said that within the past year they provided chemotherapy to at least one patient who was taking a dietary supplement. The researchers also found that 90 percent said they would likely provide chemotherapy to a patient who insisted on taking an unknown herb -- even if their cancer was curable with conventional treatment.

"Lack of knowledge about herbs and supplements, and awareness of that lack of knowledge is probably one of the reasons why oncologists don't initiate the discussion," study author Richard Lee, M.D., medical director of the Integrative Medicine Program at the University of Texas MD Anderson Cancer Center in Houston, told HealthDay. "It's really about getting more research out there and more education so oncologists can feel comfortable having these conversations."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures

FDA OKs Doptelet for Liver Dz Patients Undergoing ...

Doptelet reduces the need for platelet transfusion or any rescue therapy on day of procedure

Slower Decline in Lung Function With Anthocyanin Intake

Slower Decline in Lung Function With Anthocyanin Intake

Slower annual rates of decline in FEV1 and FVC for those in highest quartile of anthocyanin intake

Bioengineering Feasible for Airway Reconstruction

Bioengineering Feasible for Airway Reconstruction

Bioengineered tracheal and bronchial reconstruction reported using stented aortic matrices

is free, fast, and customized just for you!

Already a member?

Sign In Now »